Síndrome de Mauriac: Uma Apresentação Rara de Uma Doença Mais Comum

Introdução: A diabetes mellitus tipo 1 (DM1) é uma doença metabólica crónica cuja incidência anual tem vindo a aumentar. Pode cursar com alterações sistémicas, como a hepatomegalia e o atraso de crescimento, decorrentes de controlo glicémico inadequado. Caso clínico: Adolescente de 14 anos com o diagnóstico de DM1 desdeos três anos de idade e com mau controlo glicémico, internada numa Unidade de Cuidados Intensivos por cetoacidose grave. Do exame objectivo destacavam-se baixa estatura, hepatomegalia não dolorosa e estadio pubertário P1, M2 de Tanner. Analiticamente apresentava aumento das transaminases, hipercolestorolemia e hipertrigliceridemia. Discussão: A síndrome de Mauriac, caracteriza -se por: DM tipo 1 mal controlada, baixa estatura, atraso pubertário, hipercolesterolémia, aumento das transaminases e hepatomegalia por depósito hepático de glicogénio. O mecanismo fi siopatológico não está totalmente esclarecido, sendo provavelmente a combinação de vários factores etiológicos. É uma situação rara, cujo diagnóstico, essencialmente clínico, assume extrema importância dada a reversibilidade do quadro com a optimização terapêutica.

La souffrance féminine chez Huysmans, Bloy, Bernanos et Mauriac : catholicisme et maladie mentale

Silence et soumission aux valeurs patriarcales dominantes : ainsi peut être brossée dans son ensemble et sans pour autant la déformer l’image de la condition féminine encore pleinement opérante à la fin du XIXe siècle et au début du XXe siècle en France. La femme, ouvrière, bourgeoise ou noble, est destinée à la maternité, et ses désirs sont méprisés au profit de ceux de son (futur) époux. En littérature cependant, à partir de Madame Bovary (1857) et parallèlement à la montée timide du féminisme, apparaissent plusieurs figures féminines éminemment tragiques qui contestent la condition féminine. Louise Marles, Véronique Cheminot, Mouchette et Thérèse Desqueyroux – et tant d’autres encore… – sont autant de (jeunes) personnages féminins qui rejettent plus ou moins violemment la mise sous tutelle de la femme et l’impossibilité d’avoir un statut social et juridique accepté en dehors du mariage. Pourtant, parce qu’en ces figures de femme – et souvent malgré elles – refuse de se taire une torturante aspiration à la liberté, elles sont fatalement vouées à la folie et à la mort, deviennent prostituées, criminelles, internées ou suicidaires, voire les quatre. Selon nous, la folie est l’état dans lequel ces personnages féminins s’enlisent car ils remettent profondément en question les valeurs établies par des hommes et pour des hommes. Nous pensons que la folie est le moyen littéraire utilisé par les écrivains pour montrer l’ampleur de leur souffrance existentielle et son unique langage possible ; en ce sens, la folie serait la représentation extérieure d’une écrasante souffrance morale et psychologique. Enfin, la possession diabolique est une autre cause portée par Bernanos pour répondre à la question de la folie des femmes. Notre étude portera sur quatre figures tragiques de personnages féminins imaginées par quatre écrivains catholiques : Louise dans En rade (Huysmans, 1887), Véronique dans Le Désespéré (Léon Bloy, 1887), Mouchette dans Sous le soleil de Satan (Bernanos, 1926) et Thérèse Desqueyroux dans le roman éponyme de Mauriac (1927).

Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT

Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor-positive (HR +) breast cancer. Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure. Materials and Methods Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) is a randomized, double-blind, placebo controlled, multicenter phase III trial of fulvestrant versus exemestane in postmenopausal women with HR + advanced breast cancer (ABC) progressing or recurring after nonsteroidal AI. The primary end point was time to progression (TTP). A fulvestrant loading-dose (LD) regimen was used: 500 mg intramuscularly on day 0, 250 mg on days 14, 28, and 250 mg every 28 days thereafter. Exemestane 25 mg orally was administered once daily. Results A total of 693 women were randomly assigned to fulvestrant (n = 351) or exemestane ( n = 342). Approximately 60% of patients had received at least two prior endocrine therapies. Median TTP was 3.7 months in both groups ( hazard ratio = 0.963; 95% CI, 0.819 to 1.133; P = .6531). The overall response rate ( 7.4% v 6.7%; P = .736) and clinical benefit rate ( 32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane respectively. Median duration of clinical benefit was 9.3 and 8.3 months, respectively. Both treatments were well tolerated, with no significant differences in the incidence of adverse events or quality of life. Pharmacokinetic data confirm that steady-state was reached within 1 month with the LD schedule of fulvestrant. Conclusion Fulvestrant LD and exemestane are equally active and well-tolerated in a meaningful proportion of postmenopausal women with ABC who have experienced progression or recurrence during treatment with a nonsteroidal AI.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BACKGROUND: The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer. It is unknown whether sequential treatment with tamoxifen and letrozole is superior to letrozole therapy alone. METHODS: In this randomized, phase 3, double-blind trial of the treatment of hormone-receptor-positive breast cancer in postmenopausal women, we randomly assigned women to receive 5 years of tamoxifen monotherapy, 5 years of letrozole monotherapy, or 2 years of treatment with one agent followed by 3 years of treatment with the other. We compared the sequential treatments with letrozole monotherapy among 6182 women and also report a protocol-specified updated analysis of letrozole versus tamoxifen monotherapy in 4922 women. RESULTS: At a median follow-up of 71 months after randomization, disease-free survival was not significantly improved with either sequential treatment as compared with letrozole alone (hazard ratio for tamoxifen followed by letrozole, 1.05; 99% confidence interval [CI], 0.84 to 1.32; hazard ratio for letrozole followed by tamoxifen, 0.96; 99% CI, 0.76 to 1.21). There were more early relapses among women who were assigned to tamoxifen followed by letrozole than among those who were assigned to letrozole alone. The updated analysis of monotherapy showed that there was a nonsignificant difference in overall survival between women assigned to treatment with letrozole and those assigned to treatment with tamoxifen (hazard ratio for letrozole, 0.87; 95% CI, 0.75 to 1.02; P=0.08). The rate of adverse events was as expected on the basis of previous reports of letrozole and tamoxifen therapy. CONCLUSIONS: Among postmenopausal women with endocrine-responsive breast cancer, sequential treatment with letrozole and tamoxifen, as compared with letrozole monotherapy, did not improve disease-free survival. The difference in overall survival with letrozole monotherapy and tamoxifen monotherapy was not statistically significant. (ClinicalTrials.gov number, NCT00004205.)

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

BACKGROUND: Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up. METHODS: BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other. Randomisation was done with permuted blocks, and stratified according to the two-arm or four-arm randomisation option, participating institution, and chemotherapy use. Patients, investigators, data managers, and medical reviewers were masked. The primary efficacy endpoint was disease-free survival (events were invasive breast cancer relapse, second primaries [contralateral breast and non-breast], or death without previous cancer event). Secondary endpoints were overall survival, distant recurrence-free interval (DRFI), and breast cancer-free interval (BCFI). The monotherapy comparison included patients randomly assigned to tamoxifen or letrozole for 5 years. In 2005, after a significant disease-free survival benefit was reported for letrozole as compared with tamoxifen, a protocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen alone; Cox models and Kaplan-Meier estimates with inverse probability of censoring weighting (IPCW) are used to account for selective crossover to letrozole of patients (n=619) in the tamoxifen arm. Comparison of sequential treatments to letrozole monotherapy included patients enrolled and randomly assigned to letrozole for 5 years, letrozole for 2 years followed by tamoxifen for 3 years, or tamoxifen for 2 years followed by letrozole for 3 years. Treatment has ended for all patients and detailed safety results for adverse events that occurred during the 5 years of treatment have been reported elsewhere. Follow-up is continuing for those enrolled in the four-arm option. BIG 1-98 is registered at clinicaltrials.govNCT00004205. FINDINGS: 8010 patients were included in the trial, with a median follow-up of 8·1 years (range 0-12·4). 2459 were randomly assigned to monotherapy with tamoxifen for 5 years and 2463 to monotherapy with letrozole for 5 years. In the four-arm option of the trial, 1546 were randomly assigned to letrozole for 5 years, 1548 to tamoxifen for 5 years, 1540 to letrozole for 2 years followed by tamoxifen for 3 years, and 1548 to tamoxifen for 2 years followed by letrozole for 3 years. At a median follow-up of 8·7 years from randomisation (range 0-12·4), letrozole monotherapy was significantly better than tamoxifen, whether by IPCW or intention-to-treat analysis (IPCW disease-free survival HR 0·82 [95% CI 0·74-0·92], overall survival HR 0·79 [0·69-0·90], DRFI HR 0·79 [0·68-0·92], BCFI HR 0·80 [0·70-0·92]; intention-to-treat disease-free survival HR 0·86 [0·78-0·96], overall survival HR 0·87 [0·77-0·999], DRFI HR 0·86 [0·74-0·998], BCFI HR 0·86 [0·76-0·98]). At a median follow-up of 8·0 years from randomisation (range 0-11·2) for the comparison of the sequential groups with letrozole monotherapy, there were no statistically significant differences in any of the four endpoints for either sequence. 8-year intention-to-treat estimates (each with SE ≤1·1%) for letrozole monotherapy, letrozole followed by tamoxifen, and tamoxifen followed by letrozole were 78·6%, 77·8%, 77·3% for disease-free survival; 87·5%, 87·7%, 85·9% for overall survival; 89·9%, 88·7%, 88·1% for DRFI; and 86·1%, 85·3%, 84·3% for BCFI. INTERPRETATION: For postmenopausal women with endocrine-responsive early breast cancer, a reduction in breast cancer recurrence and mortality is obtained by letrozole monotherapy when compared with tamoxifen montherapy. Sequential treatments involving tamoxifen and letrozole do not improve outcome compared with letrozole monotherapy, but might be useful strategies when considering an individual patient's risk of recurrence and treatment tolerability. FUNDING: Novartis, United States National Cancer Institute, International Breast Cancer Study Group.

El ser y el parecer en Thérèse Desqueyroux.

El personaje de una novela tiene el papel principal, organizándose los demás elementos de la narración a partir de él. Existen tres clases de relaciones posibles entre los personajes: amor, comunicación y ayuda. Pero no olvidemos una relación que está presente en estas tres, es la relación del ser y del parecer. En efecto cada acción puede parecer a primera vista amor, confidencia, para revelarse luego como otra relación: odio, oposición..La apariencia no coincide necesariamente con la esencia de la relación. La existencia de estos dos niveles destaca claramente en la novela de François Mauriac, Thérèse Desqueyroux. La heroína se relaciona con los principales personajes (Anne, Bernard, Marie, Jean) de la novela y tratar de ver si otro elemento de la narración, el léxico coinciden con estos niveles del ser y del parecer. En definitiva, analizando las relaciones de Teresa con los principales personajes de la novela hemos constatado los dos niveles, el ser y el parecer. En este último nivel abunda todo un léxico referente a la mentira. El campo de la verdad es menor, lo que prueba la importancia de la mentira en esta novela y plena coincidencia del elemento lexicográfico con las relaciones del personaje principal.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial

PURPOSE: Previous analyses of adjuvant studies of aromatase inhibitors versus tamoxifen, including the Breast International Group (BIG) 1-98 study, have suggested a small numerical excess of cardiac adverse events (AEs) on aromatase inhibitors, a reduction in the incidence of hypercholesterolemia on tamoxifen, and significantly higher incidence of thromboembolic AEs on tamoxifen. The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98. PATIENTS AND METHODS: Eight thousand twenty-eight postmenopausal women with receptor-positive early breast cancer were randomly assigned (double-blind) between March 1998 and May 2003 to receive 5 years of adjuvant endocrine therapy with letrozole, tamoxifen, or a sequence of these agents. Seven thousand nine hundred sixty-three patients who actually received therapy are included in this safety analysis, which focuses on cardiovascular events. AE recording ceased 30 days after therapy completion (or after switch on the sequential arms). RESULTS: Baseline comorbidities were balanced. At a median follow-up time of 30.1 months, we observed similar overall incidence of cardiac AEs (letrozole, 4.8%; tamoxifen, 4.7%), more grade 3 to 5 cardiac AEs on letrozole (letrozole, 2.4%; tamoxifen, 1.4%; P = .001)--an excess only partially attributable to prior hypercholesterolemia--and more overall (tamoxifen, 3.9%; letrozole, 1.7%; P < .001) and grade 3 to 5 thromboembolic AEs on tamoxifen (tamoxifen, 2.3%; letrozole, 0.9%; P < .001). There was no significant difference between tamoxifen and letrozole in incidence of hypertension or cerebrovascular events. CONCLUSION: The present safety analysis, limited to cardiovascular AEs in BIG 1-98, documents a low overall incidence of cardiovascular AEs, which differed between treatment arms.

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

BACKGROUND: Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should be given upfront or sequentially with tamoxifen. Awaiting results from ongoing randomized trials, we examined prognostic factors of an early relapse among patients in the BIG 1-98 trial to aid in treatment choices. PATIENTS AND METHODS: Analyses included all 7707 eligible patients treated on BIG 1-98. The median follow-up was 2 years, and the primary end point was breast cancer relapse. Cox proportional hazards regression was used to identify prognostic factors. RESULTS: Two hundred and eighty-five patients (3.7%) had an early relapse (3.1% on letrozole, 4.4% on tamoxifen). Predictive factors for early relapse were node positivity (P < 0.001), absence of both receptors being positive (P < 0.001), high tumor grade (P < 0.001), HER-2 overexpression/amplification (P < 0.001), large tumor size (P = 0.001), treatment with tamoxifen (P = 0.002), and vascular invasion (P = 0.02). There were no significant interactions between treatment and the covariates, though letrozole appeared to provide a greater than average reduction in the risk of early relapse in patients with many involved lymph nodes, large tumors, and vascular invasion present. CONCLUSION: Upfront letrozole resulted in significantly fewer early relapses than tamoxifen, even after adjusting for significant prognostic factors.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial

PURPOSE: To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial. METHODS: This report includes the 4,922 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial. The median follow-up was 40.4 months. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was used to examine the patterns of differences in disease-free survival and incidences of AEs according to age. In addition, three categoric age groups were defined: "younger postmenopausal" patients were younger than 65 years (n = 3,127), "older" patients were 65 to 74 years old (n = 1,500), and "elderly" patients were 75 years of age or older (n = 295). RESULTS: Efficacy results for subpopulations defined by age were similar to the overall trial results: Letrozole significantly improved disease-free survival (DFS), the primary end point, compared with tamoxifen. Elderly patients were less likely to complete trial treatment, but at rates that were similar in the two treatment groups. The incidence of bone fractures, observed more often in the letrozole group, did not differ by age. In elderly patients, letrozole had a significantly higher incidence of any grade 3 to 5 protocol-specified non-fracture AE compared with tamoxifen (P = .002), but differences were not significant for thromboembolic or cardiac AEs. CONCLUSION: Adjuvant treatment with letrozole had superior efficacy (DFS) compared with tamoxifen in all age groups. On the basis of a small number of patients older than 75 years (6%), age per se should not unduly affect the choice of adjuvant endocrine therapy.

Presentación : "La internacional de los buenos sentimientos", de Louis Althusser

Se trata de la presentación de la traducción de "Lai nternacional de los buenos sentimientos" el primer texto de Louis Althusser del que tengamos conocimiento (1946) que permaneció inédito hasta 1994. El texto es la intervención de un joven intelectual católico, ya en tránsito hacia el comunismo, frente al movimiento internacional promovido por diferentes intelectuales (Camus, Marcel, Mauriac, Malraux, Koestler y otros), conocido como "Frente humano", enfocado a enfrentar el riesgo de la aniquilación de la especie a través de la bomba atómica. La amenaza nuclear definiría así una condición existencial novedosa, verdaderamente universal, una suerte de "proletariado del miedo" construido por los nuevos "medios y relaciones de destrucción masiva". El escrito de Althusser devela en este movimiento, por un lado, la velada intención de promover un "socialismo sin lucha de clases" como barrera a la amenaza soviética. Pero lo más interesante es que Althusser consigue también cuestionar, en sus propios términos, la matriz presuntamente antitotalitaria que sustentalas posiciones del "Frente humano": la misma exigiría la posposición de todoreclamo sectorial debería ser pospuesto ya que las mismas sólo pueden tenerderivas totalitarias o apocalípticas. Reconociendo la matriz teológica de este discurso, Althusser desnuda que esta denuncia de los "falsos profetas" es en realidad herética, ya que se sustenta, sin reconocerlo, en una profecía sobre la inevitabilidad de la catástrofe que encubre que la misma no es un asunto del mañana, sino algo que está entre nosotros, desde anteayer. Su texto constituye, así, al decir de Montag, una crítica religiosa de la escatología. En nuestra presentación examinamos la concepción de la filosofía a lo largo dela oba de Althusser, recogemos la sugerencia de Warren Montag acerca de cómoeste texto sirve para cuestionar la ontologización del vacío presente en algunos escritos tardíos de Althusser y señalamos la vinculación de este texto con un campo ideológico constituido en Argentina en la época de la transición democrática (nos centramos en Carlos S. Nino y León Rozitchner), proseguido en una intensa polémica acaecida en el interior la izquierda argentina, el debate denominado "No matar", desatado por una carta del filósofo Oscar del Barco en 2004

Presentación : "La internacional de los buenos sentimientos", de Louis Althusser

Se trata de la presentación de la traducción de "Lai nternacional de los buenos sentimientos" el primer texto de Louis Althusser del que tengamos conocimiento (1946) que permaneció inédito hasta 1994. El texto es la intervención de un joven intelectual católico, ya en tránsito hacia el comunismo, frente al movimiento internacional promovido por diferentes intelectuales (Camus, Marcel, Mauriac, Malraux, Koestler y otros), conocido como "Frente humano", enfocado a enfrentar el riesgo de la aniquilación de la especie a través de la bomba atómica. La amenaza nuclear definiría así una condición existencial novedosa, verdaderamente universal, una suerte de "proletariado del miedo" construido por los nuevos "medios y relaciones de destrucción masiva". El escrito de Althusser devela en este movimiento, por un lado, la velada intención de promover un "socialismo sin lucha de clases" como barrera a la amenaza soviética. Pero lo más interesante es que Althusser consigue también cuestionar, en sus propios términos, la matriz presuntamente antitotalitaria que sustentalas posiciones del "Frente humano": la misma exigiría la posposición de todoreclamo sectorial debería ser pospuesto ya que las mismas sólo pueden tenerderivas totalitarias o apocalípticas. Reconociendo la matriz teológica de este discurso, Althusser desnuda que esta denuncia de los "falsos profetas" es en realidad herética, ya que se sustenta, sin reconocerlo, en una profecía sobre la inevitabilidad de la catástrofe que encubre que la misma no es un asunto del mañana, sino algo que está entre nosotros, desde anteayer. Su texto constituye, así, al decir de Montag, una crítica religiosa de la escatología. En nuestra presentación examinamos la concepción de la filosofía a lo largo dela oba de Althusser, recogemos la sugerencia de Warren Montag acerca de cómoeste texto sirve para cuestionar la ontologización del vacío presente en algunos escritos tardíos de Althusser y señalamos la vinculación de este texto con un campo ideológico constituido en Argentina en la época de la transición democrática (nos centramos en Carlos S. Nino y León Rozitchner), proseguido en una intensa polémica acaecida en el interior la izquierda argentina, el debate denominado "No matar", desatado por una carta del filósofo Oscar del Barco en 2004

Cain, where is your brother? /

Mode of access: Internet.

L'adieu à l'adolescence, poème.

Forty-eight poems in four groups.